Tech-enabled pharmacies reflect the reality of the GLP-1 landscape: patient success depends on more than a prescription. With ...

Section 232 introduces a staged tariff regime: 100% default for patented drugs/APIs/KSMs, reduced 20% with approved onshoring plans, and temporary 0% if paired with MFN pricing until 2029. Deadlines ...

Dual BAFF/APRIL blockade targets upstream B-cell survival signaling to reduce production of galactose-deficient IgA1 and anti–Gd-IgA1 autoantibodies driving nephritogenic immune complexes. ORIGIN 3 ...

Clinician-led engagement outperforms non-clinical call-center models, with “nurse ambassador” programs enabling escalation, ...

Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch. Bansi Nagji, CEO of PANTHERx Rare, explores how ...

Only 18% of payers report using RWE in coverage decisions despite 80% expressing demand, reflecting a market access disconnect driven primarily by interpretability and usability barriers. Payers’ ...

Seven firms were selected for a two-phase FDA program linking new US manufacturing facilities to planned NDA/BLA/ANDA filings or supplements, targeting supply needs and unmet medical needs. Phase 1 ...

China's 2026 supply chain rules mean routine US trade compliance can now trigger Chinese export restrictions. China's new pharmaceutical supply chain regulations have transformed a chronic ...

Active shortages reached 323 in Q1 2024, with persistent durations and major chemotherapy impact; the burden includes rationing, delayed/canceled care, and substantial hospital labor costs. Generic ...

Gerren McHam of the API Innovation Center outlines what a whole-of-government approach to meaningful pharmaceutical supply chain independence from China actually requires. As McHam notes, much of the ...

Capital is flowing into CGTs, while outpatient CAR-T delivery reached 45% in 2025, expanding the number of administration sites requiring specialized, time-critical logistics support. Maintaining vein ...

Gerren McHam of the API Innovation Center on what a resilient US pharmaceutical supply chain looks like in five to ten years, and what execution actually requires. In the final part of his interview ...